Celsion Corporation  

(Public, NASDAQ:CLSN)   Watch this stock  
Find more results for CLSN
2.21
-0.14 (-5.96%)
Jul 7 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.18 - 2.42
52 week 2.15 - 3.73
Open 2.41
Vol / Avg. 275,219.00/143,321.00
Mkt cap 53.80M
P/E     -
Div/yield     -
EPS -1.40
Shares 23.00M
Beta 1.49
Inst. own 19%
Aug 11, 2015
Celsion Corp Annual Shareholders Meeting - 4:00AM EDT - Add to calendar
Aug 5, 2015
Q2 2015 Celsion Corp Earnings Release (Estimated) Add to calendar
Jul 8, 2015
Celsion Corp at Cantor Fitzgerald Inaugural Healthcare Conference - 4:12PM EDT - Add to calendar
May 12, 2015
Q1 2015 Celsion Corp Earnings Call
May 12, 2015
Q1 2015 Celsion Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -5604.06% -5098.85%
Operating margin -5268.30% -4900.25%
EBITD margin - -4592.12%
Return on average assets -44.43% -45.38%
Return on average equity -94.40% -79.24%
Employees 28 -
CDP Score - -

Address

997 Lenox Dr Ste 100
LAWRENCE TOWNSHIP, NJ 08648-2317
United States - Map
+1-609-8969100 (Phone)
+1-609-8962200 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Celsion Corporation (Celsion) is an oncology drug development company. The Company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, immunotherapies and ribonucleic acid (RNA)- or deoxyribonucleic acid (DNA)-based therapies. Its lead program is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian and brain cancers. The Company has three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, nucleic acid-based immunotherapies and other anti-cancer DNA or RNA therapies, including TheraPlas and TheraSilence.

Officers and directors

Jeffrey W. Church CPA Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer
Age: 58
Bio & Compensation  - Reuters
Khursheed Anwer Ph.D. Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy
Age: 55
Bio & Compensation  - Reuters
Nicholas Borys M.D. Senior Vice President and Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Michael H. Tardugno Executive Chairman of the Board, President, Chief Executive Officer
Age: 64
Bio & Compensation  - Reuters
Pok Yu Chow Ph.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Frederick J. Fritz Independent Director
Age: 64
Bio & Compensation  - Reuters
Robert W. Hooper Independent Director
Age: 68
Bio & Compensation  - Reuters
Alberto R. Martinez M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters